IT1179444B - Composizione farmaceutica a base di estratto solubile in piridina e di endotossina detossicata raffinata e suo impiego - Google Patents

Composizione farmaceutica a base di estratto solubile in piridina e di endotossina detossicata raffinata e suo impiego

Info

Publication number
IT1179444B
IT1179444B IT48894/84A IT4889484A IT1179444B IT 1179444 B IT1179444 B IT 1179444B IT 48894/84 A IT48894/84 A IT 48894/84A IT 4889484 A IT4889484 A IT 4889484A IT 1179444 B IT1179444 B IT 1179444B
Authority
IT
Italy
Prior art keywords
pharmaceutical composition
refined
endotoxin
detoxic
pyridin
Prior art date
Application number
IT48894/84A
Other languages
English (en)
Italian (it)
Other versions
IT8448894A0 (it
Inventor
John Leonard Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of IT8448894A0 publication Critical patent/IT8448894A0/it
Application granted granted Critical
Publication of IT1179444B publication Critical patent/IT1179444B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT48894/84A 1983-09-23 1984-09-24 Composizione farmaceutica a base di estratto solubile in piridina e di endotossina detossicata raffinata e suo impiego IT1179444B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use

Publications (2)

Publication Number Publication Date
IT8448894A0 IT8448894A0 (it) 1984-09-24
IT1179444B true IT1179444B (it) 1987-09-16

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
IT48894/84A IT1179444B (it) 1983-09-23 1984-09-24 Composizione farmaceutica a base di estratto solubile in piridina e di endotossina detossicata raffinata e suo impiego

Country Status (23)

Country Link
US (1) US4663306A (OSRAM)
JP (1) JPS60120817A (OSRAM)
KR (1) KR870000843B1 (OSRAM)
AT (1) AT385659B (OSRAM)
AU (1) AU566234B2 (OSRAM)
BE (1) BE900650A (OSRAM)
CA (1) CA1244765A (OSRAM)
CH (1) CH664897A5 (OSRAM)
DE (1) DE3434766C2 (OSRAM)
DK (1) DK446684A (OSRAM)
ES (1) ES8608872A1 (OSRAM)
FI (1) FI843716A7 (OSRAM)
FR (1) FR2552326B1 (OSRAM)
GB (1) GB2149301B (OSRAM)
HU (1) HU192585B (OSRAM)
IL (1) IL73034A (OSRAM)
IN (1) IN157240B (OSRAM)
IT (1) IT1179444B (OSRAM)
NL (1) NL8402902A (OSRAM)
NO (1) NO843776L (OSRAM)
NZ (1) NZ209635A (OSRAM)
SE (1) SE8404707L (OSRAM)
ZA (1) ZA847405B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
EP0714305B1 (en) * 1993-08-27 2001-12-19 Vetrepharm, Inc. Composition and method for stimulation of reproductive performance
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
PT1003525E (pt) 1997-08-05 2003-03-31 Bioniche Life Sciences Inc Composicao e metodo para a regulacao da proliferacao e da morte celular
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
WO2000003724A1 (en) * 1998-07-16 2000-01-27 Hayashi, Akira Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
DK1238070T3 (da) * 1999-12-13 2007-12-03 Bioniche Life Sciences Inc Terapeutisk anvendelige syntetiske oligonucleotider
EP1250152B1 (en) * 1999-12-28 2013-05-15 Bioniche Urology IP Inc. Synergistic composition containing hyaluronic acid in the treatment of cancer
SI21171A (sl) * 2000-07-11 2003-10-31 Bayer Aktiengesellschaft Uporaba sevov parapoksvirusa ovis proti fibrozi organov
CA2478106A1 (en) * 2002-03-05 2003-09-12 Cell-Medicine, Inc. Solidified tissue immunoadjuvant
WO2004012751A1 (ja) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited 細菌細胞壁骨格成分製剤
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
US20060127518A1 (en) * 2003-09-05 2006-06-15 Shenyang Sunbellcom Bio-Pharmaceutical Co. Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA2950945A1 (en) 2014-06-17 2015-12-23 Xycrobe Therapeutics, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
WO2017147507A1 (en) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Skin probiotic formulation
US20210040055A1 (en) * 2017-08-17 2021-02-11 University Of Delaware Furan based compositions and methods of making thereof
WO2021262622A1 (en) 2020-06-23 2021-12-30 Crown Laboratories, Inc. Probiotic skin formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (OSRAM) * 1972-06-20 1973-12-27
FR2269962B1 (OSRAM) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白ｗｅｎａｃ及びその製造法
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism

Also Published As

Publication number Publication date
FI843716L (fi) 1985-03-24
ZA847405B (en) 1985-05-29
FI843716A0 (fi) 1984-09-21
US4663306A (en) 1987-05-05
GB8423993D0 (en) 1984-10-31
IL73034A (en) 1988-11-15
FR2552326A1 (fr) 1985-03-29
DE3434766A1 (de) 1986-04-30
JPS6254775B2 (OSRAM) 1987-11-17
AT385659B (de) 1988-05-10
HU192585B (en) 1987-06-29
JPS60120817A (ja) 1985-06-28
SE8404707L (sv) 1985-03-24
NO843776L (no) 1985-03-25
ATA302384A (de) 1987-10-15
IT8448894A0 (it) 1984-09-24
IN157240B (OSRAM) 1986-02-15
CH664897A5 (de) 1988-04-15
AU3340084A (en) 1985-03-28
DK446684A (da) 1985-03-24
HUT35521A (en) 1985-07-29
SE8404707D0 (sv) 1984-09-20
KR870000843B1 (ko) 1987-04-25
FR2552326B1 (fr) 1988-05-13
ES8608872A1 (es) 1986-07-16
NZ209635A (en) 1989-01-27
GB2149301B (en) 1988-06-22
BE900650A (fr) 1985-03-21
DE3434766C2 (de) 1987-05-14
DK446684D0 (da) 1984-09-19
ES536167A0 (es) 1986-07-16
KR850002404A (ko) 1985-05-13
AU566234B2 (en) 1987-10-15
GB2149301A (en) 1985-06-12
FI843716A7 (fi) 1985-03-24
CA1244765A (en) 1988-11-15
NL8402902A (nl) 1985-04-16

Similar Documents

Publication Publication Date Title
IT1179444B (it) Composizione farmaceutica a base di estratto solubile in piridina e di endotossina detossicata raffinata e suo impiego
ATE116993T1 (de) Saponin-hilfsmittel.
IT8048102A0 (it) Procedimento di preparazione di un idrolisato di proteine purificato
MX9302199A (es) Aditivo para vacuna.
BG31496A3 (bg) Метод за получаване на 4-амино-5-алкил-сулфонил ортоанизамиди
BG44538A3 (bg) Метод за получаване на соли на 5-метокси-2-голяма скоба(4 метокси- 3,5-диметил-2-пиридинил)-метил сулфонил голяма скоба-1н-бензимидазол
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DK173883D0 (da) Substituerede 8-phenylxanthiner
EP0283505A4 (en) Vaccine and method of preparation.
BG38334A3 (en) Method for preparing pyrolidinic derivatives
NL990018I1 (nl) Vaccin tegen Pasteurella.
BG38489A3 (en) Method for preparing oxazophosphorine- 6, 4- thiolcalsulphonic acids and their neutral salts
BG38638A3 (bg) Метод за получаване на арилциклобутил-аминопроизводни
FI880954A7 (fi) Seos ja menetelmä immunologista kastrointia varten.
SE8003433L (sv) Substituerade pyrido(1,2-a)pyrimidiner
BG36495A3 (bg) Метод за получаване на 4-хинолови производни
IT209389Z2 (it) Struttura di album raccoglitore particolarmente per fotografie e simili.
BG35897A3 (bg) Метод за получаване на 5-(дихидрокси-фенокси)-1н-тетразоли
IT1177974B (it) Composizione comprendente endotossina detossificata raffinata
BG38338A3 (en) Method for preparing 6 alpha- methylhydrocortisonic derivatives
NL194960B (nl) Werkwijze voor het bereiden van mutantstammen van Bordetella bronchiseptica en daarop gebaseerd levend verzwakt vaccin.
DK340079A (da) Vaccine og vaccination for svinedysenteri
KR930703006A (ko) 백신, 특히 돼지의 흉막폐염 백신의 면역강화
BG35598A3 (en) Method for preparing indolizinic derivatives
IT9019691A0 (it) Metodo perfezionato di decatizzo in autoclave